Clinical Trials on Childhood T Acute Lymphoblastic Leukemia

Total 4868 results

National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Recurrent Childhood Acute Lymphoblastic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Childhood T Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
ECOG-ACRIN Cancer Research Group

Recruiting

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Childhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Untreated Childhood Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Neurotoxicity Syndrome | Childhood B Acute Lymphoblastic Leukemia | Cognitive Side Effects of Cancer Therapy | Psychological Impact of Cancer | Long-Term Effects Secondary to Cancer Therapy in Children

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)
Children's Cancer Group

Completed

506U78 in Treating Patients With Refractory Hematologic Cancer

Recurrent Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Lymphoblastic Lymphoma

United States
Therapeutic Advances in Childhood Leukemia Consortium
Enzon Pharmaceuticals, Inc.

Terminated

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T Cell

United States, Australia
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
Northwestern University
National Cancer Institute (NCI)

Terminated

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Refractory Childhood Acute Lymphoblastic Leukemia

United States
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
Sanofi

Terminated

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)

T-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/Leukaemia

Hungary, United States, Finland, France, Italy, Lithuania, Russian Federation
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); The Leukemia...

Terminated

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

T-Acute Lymphoblastic Leukemia | Adult T Lymphoblastic Lymphoma

United States
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Recruiting

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

T-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

T-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | Early T Acute Lymphoblastic Leukemia | Etp All

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Canada, Australia, New Zealand, Puerto Rico
National Cancer Institute (NCI)

Terminated

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI); ImmunoGen, Inc.

Withdrawn

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

T-Cell Acute Lymphoblastic Leukemia

China
Ehab L Atallah

Recruiting

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Acute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University

Recruiting

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
Medical College of Wisconsin
University of Wisconsin, Madison; Amgen

Recruiting

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

B-cell Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | B-Cell ALL, Childhood

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
Shenzhen BinDeBio Ltd.
Children's Hospital of Fudan University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China

Clinical Trials on Childhood T Acute Lymphoblastic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations